The CD2 antigen is the target for an "alternative" T cell activation pathway. Numerous studies have demonstrated that pairs of monoclonal antibodies (mAbs) directed toward two different epitopes are required for activation of T cell receptor (TCR)-c1/0+ T cells via CD2 . We have now explored the activation of human TCR-y/b+ T cell clones by a panel of anti-CD2 mAbs directed against the sheep erythrocyte-binding (T11 .1) epitope of CD2. Seven of seven -Y/b+ clones expressing different molecular forms of the TCR-y/b responded to stimulation by a single anti-CD2 mAb (OKT11, 9E8, BW0110, M -T910) with IL-2 secretion and/or proliferation . Immobilization of anti-CD2 mAbs in microculture plates was essential for activation of 'r/b + clones, which occurred in the absence of feeder cells . In addition to interleukin 2 (1172) production and proliferation, anti-CD2 mAbs also triggered cytotoxic effector activity in 'r/b + clones as measured against FcR+ P815 target cells . In contrast to y/b+ clones (but in line with established data), none of five CD4+ or CD8+ TCR-a/(3+ clones were activated by any of the tested individual anti-CD2 mAbs. Taken together, our results reveal a striking difference between cloned y/b+ and a/a+ T cells in that y/b+ T cells are selectively activated by a single anti-CD2 (T11 .1) mAb, without need for the simultaneous signal of a second anti-CD2 mAb directed against another (T11 .2 or T11.3) CD2 epitope.
T cells are activated by the antigen-specific TCR/CD3 molecular complex following interaction with foreign antigenic peptides in association with self MHC proteins. In addition, T cells can be activated via an "alternative" pathway through the CD2 cell surface antigen (1) . CD2 is a 50-55-kD single-chain glycoprotein expressed on the vast majority of peripheral blood T cells and thymocytes (2, 3). Three epitopes have been defined on the CD2 molecule, of which T11.1 and T11 .2 are expressed on resting T cells, while T11.3 (now designated C132R) is a conformational epitope that only appears after activation (1) . Soluble mAbs directed against TILL the sheep erythrocyte-binding epitope of CD2, inhibit certain T cell functions such as 11,2 production, IL-2-dependent proliferation, and cytotoxic effector activity (4) (5) (6) (7) (8) . Pairs of mAbs directed against the T11 .2 and T11.3 epitopes in combination activate resting T cells (1, 9, 10) . One of the two anti-CD2 mAbs required for T cell activation may be replaced by the natural ligand for CD2, LFA-3, by sheep erythrocytes, or by PMA (11-13) . Moreover, cytolytic activity can be triggered in CD2+CD3 -TCR -NK cells by a mitogenic combination of two anti-CD2 mAbs, or by a single anti-CD2 mAb (5, 8, 14) . In the latter case, however, CD2 must be cross-linked with CD16, the low affinity Fcy receptor (14) . Thus, it is obvious that activation of TCR-a//3+ T cells and TCR -NK cells via CD2 requires two signals.
A minor fraction of peripheral blood T cells (1-10%) express a TCRy/b heterodimer noncovalently associated with the CD3 complex (15). The biological significance, including the antigen specificity of y/b+ T cells, is still a matter of debate (15, 16) . A striking feature of -y/b+ T cells is their frequent reactivity towards mycobacterial antigens (17) (18) (19) (20) . Activation requirements of -y/b+ T cells have not been thoroughly investigated so far. Established y/b+ clones can be stimulated to secrete IL-2 and other cytokines (21) , but freshly isolated -y/b+ T cells produce less 11,2 upon PMA stimulation than do a/a+ T cells (22) .
In the present study we have analyzed the "alternative" CD2 activation pathway in cloned -y/b+ T cells. We found that single anti-CD2 (T11 .1) mAbs strongly triggered the activation of seven of seven TCR-7/6+ clones, while none out of five TCR a/a+ clones were stimulated under these conditions. These results reveal a striking difference between cloned y/b+ and a/a+ T cells regarding the CD2-dependent activation pathway.
PBMC were separated into T and non-T cells by the E rosette procedure using neuraminidase-treated sheep E. y/6' T cells were enriched from E-rosetting T cells as described (22) . Briefly, T cells were incubatedwith supernatants of OKT4 (anti-CD4) and OKT8 (anti-CD8) hybridomas (both from American Type Culture Collection, Rockville, MD). After being washed, the cells were incubated with nontoxic rabbit complement (Cedarlane Laboratories, Hornby, Ontario) for 1 h at 37°C . Dead cells were removed by Ficoll-Hypaque density gradient centrifugation . Viable cells were cultured at 0.3 cells per well in 96-well round-bottomed culture plates (Nunc, Roskilde, Denmark) in the presence of 105 irradiated PBMC feeder cells and 0.5 hg/ml PHA-P (Wellcome, Burgwedel, FRG) . The culture medium was RPMI 1640 (Biochrom KG, Berlin, FRG) supplemented with 10% heat-inactivated FCS (batch 4MO2 ; Biochrom KG), antibiotics, 2 mM L-glutamine, and 10 mM Hepes. After 2 d, rIL2 (EuroCetus, Amsterdam, The Netherlands) was added at 2 ng/ml. Growing clones were expanded in 24-well culture plates (Greiner, Ntirtingen, FRG) in rIIL2-supplemented medium. Every 10-14 d, the clones were restimulated with feeder cells (mixture of 106 irradiated PBMC per milliliter plus 105 irradiated EBVtransformed LCL per milliliter) and PHA-P (0.5 Pg/ml). In some cases, y/6+ clones were established after isolation of 7A5' (Vy9+) T cells on a cell sorter (FACStar Plus ; Becton Dickinson & Co ., Mountain View, CA) . a/o' T cell clones were obtained by culturing E-rosette separated T cells at 0.3 cells per well under the above described culture conditions.
Phenotypic Characterization of T Cell Clones. The antiTCRmAbs used for the phenotypic TCR characterization of established clones are listed in Table 1 . Commercial mAbs TCR61 and 6-TCS1 (T Cell Sciences, Cambridge, MA) were used as FITC-conjugates, whereas indirect staining procedures were applied in conjunction with noncommercial mAbs . In this case, FITC-conjugated F(ab') z goat anti-mouse IgG (Tago, Burlingame, CA) was used as a second-
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Activation of . y/S+ T Cells by Anti-CD2 Antibodies step reagent. mAbs A13 (23) and BB3 (24) were kindly provided by Dr. L. Moretta (Istituto Nationale, Genoa, Italy), and mAbs TiyA (25) Table 1 . mAb 9E8 was obtained in our laboratory from a fusion of spleen cells from a female Balb/c mouse immunized with a CD2`y/S* human T cell clone. 9E8 blocks rosette formation between human T cells and sheep E, and identifies by Western blot analysis a single band of -50 kD mol mass on resting T cells and established T cell clones (our unpublished results) . Based on these criteria, mAb 9E8 is classified as anti-CD2 . Like 9E8, all other anti-CD2 mAbs listed in Table 1 strongly react with resting T cells and block E rosette formation. Therefore, they are classified as anti-CD2 (anti-T11 .1) and not anti-CD2R mAbs (27) . Hybridoma cells producing OKT11 mAb (IgGl) were obtained from ATCC . IOT11 and IOT11a were from Dianova (Hamburg, FRG) . mAb MT910 (28) was kindly donated by Dr. E.P. Rieber (University of Munich, FRG), and mAbs BW0110, BMA030 (anti-CD3), and BMA031 were generously provided by Drs. K.H . Enssle and R. Kurrle (Behringwerke, Marburg, FRG) . mAbs OKT11 (ATCC), 9E8, OKT4 (ATCC), and 7A5 were purified from hybridoma culture supernatants on protein G columns (Pharmacia, Uppsala, Sweden).
Cell Cultures. Cloned y/6+ (and a/fl') T cells were cultured in the presence of immobilized or cross-linked anti-CD2 mAb, and IL2 produced by mAbstimulated T cell clones was detected in a colorimetric assay on IL-2-dependent murine CTLL cells as described (29) . Briefly, 15,000 CTLL cells per well were added to flat-bottomed culture plates containing supernatants of T cell clones. After incubation for 24 h at 37°C/5% CO Z , the tetrazolium salt MTT (Sigma, Deisenhofen, FRG) was added at 250 fcg/ml, and incubation was continued for another 4 h. Formazan crystals were solubilized in 10% SDS/1% HCl, and OD at 570 nm were read on an ELISA reader with the reference wave length set at 690 nm . This assay is highly specific for IL2 ; the CTLL clone used does not respond to human rILl, rIL3, or rl1r4 (29) .
Cytotoxicity Assay. FcR' murine P815 mastocytoma cells were used in a standard 4-h "Cr-release assay to evaluate the cytotoxic effector activity of cloned T cells in the absence or presence of different mAbs. Percentage specific lysis was calculated as follows : Percent specific lysis = 100 x [(cpmaperimentai -cpmsponunrnus)/ (cprnmiximal -cprrrsponuneous)] "
Results
Immobilized Single Anti-CD2 mAbs Stimulates Proliferation of y/b+ Clones. We have investigated possible stimulatory effects of anti-CD2 mAbs on cloned y/S' T cells. To this end, clone cells were added to mAb-coated culture plates, and [3 H]TdR incorporation was determined after 36 h o£ culture. As shown in Fig. 1 , y/S' clones strongly proliferated in response to individual immobilized anti-CD2 mAbs. All stimulatory anti-CD2 mAbs depicted in Fig. 1 were directed against the T11.1 epitope. It should be stressed, however, that stimulation of -y/S+ T cell clones could not be achieved with every anti-CD2 mAb. Among the anti-CD2 mAbs tested (see Table 1 ), OKT11 (ATCC), 9E8, M -T910, and BWO110 were stimulatory, whereas ICT11 and IOT11a were not (not shown) . There was no obvious correlation between the stimulatory capacity of a given anti-CD2 mAb and its IgG subclass. Thus, stimulatory anti-CD2 mAbs were either IgG1 ( Table 2 ) were cultured in triplicate in microculture plates previously coated with 1 jig per well of the indicated purified mAb .
[3H]TdR incorporation was determined after 36 h. The proliferative response to rIL2 (3 ng/ml) was used as a positive control .
The following mAbs were used: anti-CD2 : OKT11 (ATCC), 9138, BW (BWO110), MT (MT910); antiTCR y/b : 7A5 (antiVy9) ; anti-CD3: OKT3 ; anti-CD4: OKT4 .
by reactivity with antiVy and antiV6 mAbs (see Table 2 for phenotypic analysis) were all activated by stimulatory anti-CD2 mAbs . In contrast, activation by immobilized antiVy9 mAb 7A5 was restricted to Vy9-expressing clones (D768/6, A92DN3, D768/4, B54; see Fig. 1 ) . As a control, immobilized anti-CD4 mAb OKT4 did not stimulate CD4 -y/6' clones . A second protocol was equally efficient in eliciting CD2-dependent activation of -y/b+ clones. Here, clone cells were first incubated with anti-CD2 mAb, then washed, and cultured in microculture plates previously coated or not with goat anti-mouse Ig. Under these conditions, Vy9-expressing D768/6 clone cells strongly proliferated (Fig. 2) . No proliferative response was observed, however, when anti-CD2-labeled -y/S+ clones were cultured in microculture plates not coated with anti-mouse Ig, indicating that cross-linking of cell surface CD2 molecules was essential to trigger proliferation (Fig . 2) .
The stimulatory effect of individual immobilized anti-CD2 mAbs was strikingly specific for -y/b+ cells. As illustrated in Fig . 3 , none of five well-characterized (CD4+ or CD8 + ) TCR a//3+ clones proliferated in response to immobilized single anti-CD2 mAbs OKT11 (ATCC) or 9E8, while all of them were activated by plastic-bound anti-CD3 (OKT3) or antiTCR-a/(3 (BMA031) mAbs .
Immobilized Single Anti-CD2 mAbs Stimulate IL2 Production in y/8+ Clones. The above data showed that triggering by a single immobilized or cross-linked anti-CD2 mAb induced autocrine proliferation of -y/S+ but not ca/o+ T cell clones. To investigate whether this proliferative response was IL2 dependent, we measured IL2 in cell-free culture supernatants of anti-CD2-stimulated y/S+ clones . As shown in Fig . 4 , IL2 production was induced in all four analyzed ,y/b+ clones by at least two of the tested anti-CD2 mAbs. However, not all anti-CD2 mAbs that stimulated proliferation of a given -y/b+ clone ( Fig. 1) also triggered measurable IM production. Of interest, certain anti-CD2 mAbs were effective on some but not other -y/b+ clones. It is thus evident that the anti-CD2-triggered autocrine proliferation of y/S+ clones is not necessarily dependent on the secretion of detectable amounts of 11,2 into the culture medium .
A Single Anti-CD2 mAb Triggers Cytotoxic Ejector Function in TIP but not a/#+ Clones. Next we asked whether anti-CD2 mAbs could also trigger cytotoxic effector func- ) mAbs all triggered cytotoxic activity, whereas antiTCR-a/p mAb BMA031 was without effect. A second y/b+ clone expressing a different TCR phenotype (V-y9 -/VSl+) displayed some spontaneous cytotoxic activity against P815 target cells (Fig . 5 B) . Again, the cytotoxic activity was increased by anti-CD2 (OKT11 [ATCC]) and anti-CD3 (OKT3, BMA030) but not by mAbs 7A5 or BMA031. Triggering of cytotoxic effector function by anti-CD2 mAb OKT11 was not observed with a TCR cx/a+ clone (Fig. 5 C) . As expected, however, this clone was responsive to signaling by anti-CD3 or antiTCR-ot//3 mAbs.
Discussion
Our experiments revealed a striking difference between cloned TCR-7/6+ and MR-a/0i+ T cells with respect to stimulation via the alternative CD2 activation pathway. It is well established that the CD2-dependent activation of a/a+ T cells requires two signals provided by two mAbs directed against different epitopes of CD2 (1, 9, 10) . One of the two signals can be replaced by LFA3 (the natural ligand 30 1 Wesselborg et al. Table 2 ) were cultured,in mAb-coated plates as described in the legend to Fig . 1 . After 24 h, supernatants were transferred to flat-bottomed microculture plates, and 11,2-dependent CTLL cells were added . After additional incubation for 24 h, viability of CTLL cells was determined in a colorimetric MTT assay (29) . Results are given as mean OD x 10 -3 of triplicate cultures. rII.2 (3 ng/ml) was added to CTLL cells as a positive control . BW, BWO110 ; MT, M T910 .
for CD2), sheep E, or PMA (11-13) . We now report that stimulation with a single anti-CD2 mAb in the absence of feeder cells is sufficient to trigger IL2 production, proliferation, and cytotoxic effector activity in y/b+ clones expressing distinct molecular forms of the TCR-y/& Activation requirements of y/b+ T cells have not been thoroughly studied . A proliferative response of freshly isolated resting -y/S+ cells can be initiated by PHA, anti-CD3 mAb, or alloantigenic stimulation (22, 30) . After PHA stimulation, purified -y/S+ cells produce less 11,2 than a/a+ cells, and proliferation of y/S+ cells can be triggered in the absence of detectable amounts of secreted IL-2 (22) . In line with these results, we found that the anti-CD2 triggered proliferation of cloned y/6+ T cells was not necessarily associated with the secretion of measurable 11,2, although some anti-CD2 mAbs induced strong IL2 production . It remains to be established whether growth factor(s) other than IL2 (e .g., IL4) contribute to the autocrine proliferation of y /6+ clones in response to anti-CD2 signaling .
As shown here, established y/6+ clones are selectively activated by immobilized or cross-linked single anti-CD2 mAbs . The responsiveness of a given y/6+ clone to anti-CD2 signaling does not depend on the experimental protocol used to establish the clone . Although most clones were obtained from purified CD4 -CD8 -cells after isolation of E-rosetting T cells, several y /6+ clones were established after sorting of 7A5+ (Vy9+) T cells from unseparated PBMC . These clones were equally susceptible to anti-CD2 signaling (not shown) . The present results raise the important issue of whether this selective activation pathway is also operational in resting polyclonal y/6+ T cells . A prerequisite to address this question is the ability to isolate sufficiently pure y /6+ T cells by negative selection, so as not to interfere with CD3/TCR triggering during positive selection (e .g., cell sorting involving antiTCR mAbs) . Experiments to study 302 Activation of y/b+ T Cells by Anti-CD2 Antibodies the CD2-dependent activation pathway of primary y/6+ T cells are now in progress. Given that single anti-CD2 mAbs directed against the sheep E binding epitope stimulate y/6+ but not a/J3+ clone proliferation, one might expect similar effects utilizing sheep E instead of anti-CD2 mAb. However, under various experimental conditions, we never did observe activation (defined as cellular proliferation or IL-2 production) of cloned y/6+ T cells in the presence of sheep E only. It is thus obvious that cross-linking of the T11 .1 epitope by a single anti-CD2 mAb provides a stronger activation signal to cloned y/6+ T cells than binding of sheep E to cell surface T11.1 . In this context it is of interest that cross-linking of an individual anti-CD2 mAb induces Cat+ mobilization also in a/o' T cells, without directly stimulating T cell proliferation (31) .
TCRindependent "alternative" activation pathways have been previously studied with cloned y/6+ T cells. Interestingly enough, activation via CD28 (32) appears to be deficient in y/6+ cells, due to the lack of CD28 expression on many y/6+ T cells (33) . With regard to CD2 activation, Ferrini et al. (33) reported on the activation of y/6+ clones by an appropriate combination of two different anti-CD2 mAbs . However, data reported from other groups support our present results that y/6+, but not a/R+ T cells, can be activated by single anti-CD2 mAbs . Thus, Goedegebuure et al . (34) demonstrated that the lytic machinery can be triggered in y /6+ but not a/a+ T cell clones by bispecific heteroconjugates containing a single anti-CD2 (TIM) mAb cross-linked to anti-DNP. Recently, Pawelec et al . reported that 2 of 13 anti-CD2 mAbs from the 4th International Leukocyte Typing Workshop (35) singly stimulated autocrine y/6+ T cell clone proliferation (36) . In contrast to our results, however, the presence of EBV transformed LCL feeder cells was absolutely required in their system . Thus, no y/6+ clone activation was observed with immobilized individual anti-CD2 mAbs in the absence of feeder cells (36) . The apparent discrepancy to our present results is most likely due to the usage of different anti-CD2 mAbs in the two studies . As a matter of fact, none of the four stimulatory anti-CD2 mAbs used in our experiments (Table 1) was included in the study of Pawelec et al . (36) . It is obvious from both studies that not all anti-CD2 (T11 .1) mAbs individually activate y/6+ T cell clones, be it in the absence (this study) or presence (36) of feeder cells. It is presently unclear why certain anti-CD2 mAbs are stimulatory while others are not . The Ig isotype does not appear to be critical because IgG1 anti-CD2 included both stimulatory (OKT11 [an IgG1 reagent from AMC], 9E8, M -T910) and nonstimulatory (IOT11, OKT11 [an IgG2A reagent from Ortho Diagnostics, Raritan, NJ] ; not shown) mAbs . It will be important to precisely characterize the stimulatory mAbs with respect to the recognized epitope (37) . In this context, it is of interest that anti-CD2 (T11 .1) mAbs can be classified into two subgroups (T11 .1A, T11.1B ; reference 38) . While both T11 .1A and T11.1B mAbs block E rosette formation and inhibit binding of LFA-3, T11.1A antibodies can replace the triggering signal provided by LFA 3, whereas T11.1B antibodies exert suppressive activity (38) . In addition, it will also be important to investigate whether the signal provided by a single cross-linked anti-CD2 mAb can be replaced by LFA-3, the natural ligand for CD2 (12) .
There is evidence that the CD2 and CD3/TCR activation pathways are functionally linked at least in T cells that express both molecules (27, 39) . Activation of ot/0+ T cells via CD2 results in tyrosine phosphorylation of the CD3/TCR chain (40) , and suitable experimental conditions allow the
